Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers
Rare ovarian tumours include complex borderline ovarian tumours, sex-cord tumours, germ cell tumours and rare epithelial tumours. Indications and modalities of fertility preservation (FP), infertility management, contraindications for hormonal contraception or menopause hormone therapy are frequent issues in clinical practice. A panel of experts from the French national network dedicated to rare gynaecological cancers, and experts in reproductive medicine and gynaecology have built guidelines on FP, contraception and menopause hormone therapy in women treated for ovarian rare tumours.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Christine Rousset-Jablonski, Fr éderic Selle, Elodie Adda-Herzog, François Planchamp, Lise Selleret, Christophe Pomel, Emile Daraï, Nathalie Chabbert-Buffet, Patricia Pautier, Florence Trémollières, Frederic Guyon, Roman Rouzier, Valérie Laurence, N Tags: Current Perspective Source Type: research
More News: Borderline Tumor | Cancer | Cancer & Oncology | Epithelial Cancer | France Health | Hormonal Therapy | Hormones | Infertility | Men | Menopause | OBGYN | Ovarian Cancer | Ovaries | Reproduction Medicine | Women